Vyvanse—a medication approved in 2007 for attention-deficit/hyperactivity disorder (ADHD)—is the fir...

In a phase II clinical trial, a new compound that targets the NMDA receptor was found to quickly and...

Previous studies have suggested that medicines—both prescription and over-the-counter—aiming to bloc...

High levels of anxiety concurrent with elevated amyloid beta (Aβ) levels in the brain were significa...

Extended-release venlafaxine was well tolerated and appears to be an effective antidepressant for de...

The attention-deficit/hyperactivity disorder (ADHD) medication lisdexamfetamine dimesylate (trade na...

Reducing disparities in mental health care access for racial and ethnic minorities would lead to sub...

Patients experiencing a first-episode psychosis and treated at community based clinics had longer du...

Specific neuropsychiatric symptoms are associated with shorter survival time from mild Alzheimer’s d...